Compare AVX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | LUNG |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | Canada | United States |
| Employees | 7 | N/A |
| Industry | Metal Fabrications | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 57.9M |
| IPO Year | N/A | 2020 |
| Metric | AVX | LUNG |
|---|---|---|
| Price | $0.52 | $1.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | ★ 604.7K | 496.8K |
| Earning Date | 05-15-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $18.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.44 | $1.13 |
| 52 Week High | $2.27 | $3.88 |
| Indicator | AVX | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 45.18 |
| Support Level | $0.46 | $1.27 |
| Resistance Level | $0.60 | $1.45 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 53.72 | 37.04 |
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. It focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.